Oxaliplatin-Induced Peripheral Neuropathy Raises Concerns for Colorectal Cancer Patients

Strategic Insights -

A prospective cohort study of 129 colorectal cancer patients receiving oxaliplatin-based chemotherapy revealed that the cumulative dose of oxaliplatin plays a significant role in the development of oxaliplatin-induced peripheral neuropathy (OIPN). The research found that the occurrence of OIPN is associated with the progression of the disease, tumor markers, immune response, and inflammation. The study's findings suggest that selected biomarkers can serve as a foundation for predicting and managing OIPN in colorectal cancer patients.

Key Takeaways:

  • The cumulative dose of oxaliplatin is a significant risk factor for the development of OIPN in colorectal cancer patients.
  • Biomarkers such as CEA, CA19-9, CA72-4, ANC, PLT, GGT, and UA are associated with the occurrence of OIPN.
  • The progression of the disease is closely linked to the development of OIPN.
  • The study's findings have implications for the management and prediction of OIPN in colorectal cancer patients.
  • The identified biomarkers can serve as a foundation for developing targeted therapies to prevent or alleviate OIPN.
  • The research highlights the need for further investigation into the mechanisms underlying OIPN and the development of new treatments to mitigate its effects.

Statistics:

  • 129 colorectal cancer patients were enrolled in the study.
  • The cumulative dose of oxaliplatin was found to be a significant risk factor for OIPN.
  • 521 metabolites were detected in the serum samples analyzed.
  • Machine learning validation included six classifiers assessed via ROC-AUC.
  • The study's findings suggest that selected biomarkers can serve as a foundation for predicting and managing OIPN.

Sources:

  • Metabolome profiling by untargeted metabolomics and biomarker panel selection using machine-learning for patients in different stages of peripheral neuropathy induced by oxaliplatin. Frontiers in Oncology, 2025;15:1617207.
  • Frontiers in Oncology can be contacted at: Frontiers Media Sa, Avenue Du Tribunal Federal 34, Lausanne, Ch-1015, Switzerland.
  • The news editors report that additional information may be obtained by contacting Ying Zhang, Dept. of Medical Oncology, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, People's Republic of China.